Sharma says growing number of pharmaceutical partners seek precision
Lantern Pharma Inc. (NASDAQ: LTRN) says the new AI Centre of Excellence and Advanced Agentic Labs in Bengaluru will serve as the company’s global scale-up centre for the AI platform, providing expanded computational capacity, specialized technical talent, and follow-the-sun development cycles that enable rapid iteration and deployment of advanced AI modules and functionality.
As pharmaceutical companies increasingly shift from AI experimentation to enterprise-scale deployment, the Bengaluru centre will support both Lantern’s internal pipeline and growing roster of pharmaceutical and academic collaborators globally, said the Texas-based company.
It is a critical inflection point in its evolution — transitioning from pioneering AI-enabled drug discovery in cancer to industrializing those capabilities at global scale for the broader drug development community, Lantern said on 12 Jan https://www.bseindia.com/.
The centre will expand the technical depth and throughput of Lantern’s proprietary RADR® AI platform, which currently leverages hundreds of billions of oncology-focused data points and an expanding library of sophisticated machine learning algorithms and curated disease models and knowledge objects https://www.nseindia.com/.
“Lantern was founded on the conviction that artificial intelligence and data-driven methodologies can fundamentally redefine drug discovery paradigms,” said Panna Sharma, President & CEO of Lantern Pharma.
“Our AI Centre of Excellence represents the industrialization of that vision—scaling proven RADR® capabilities to serve the growing number of pharmaceutical partners seeking precision, data-guided therapies across oncology and beyond with increasingly more aggressive timelines https://digitalinasia.com/.
“This initiative strategically positions Lantern at the forefront of the pharmaceutical industry’s transformation from computational experimentation to systematic, AI-powered therapeutic development that addresses critical unmet patient needs globally. Our approach simultaneously plays a central role in containing development costs and increasing R&D efficiency.”
“We have reached a defining inflection point where artificial intelligence, genomic science, and clinical data are converging to fundamentally transform drug discovery from empirical experimentation to systematic, data-driven precision,” said Dr Vijay Chandru, Board Member of Lantern Pharma since 2019, World Economic Forum Technology Pioneer, and longtime mentor to life sciences and technology ventures in India http://who.int.
“Bengaluru represents one of the rare global ecosystems possessing the complete technical infrastructure required to lead this transformation: world-class AI and data engineering talent, a rapidly maturing biotech research community, and proven computational capabilities at scale,” he said.
The AI Centre of Excellence is strategically significant—it demonstrates that Bengaluru has evolved beyond pilot-phase experimentation and is now positioned to industrialize AI-powered therapeutic development at global scale,” elaborated Dr Chandru https://www.wto.org/.
“By bringing the proven RADR® oncology platform into this ecosystem and leveraging Bangalore’s exceptional technical depth, Lantern creates a foundation for systematic acceleration across cancer therapeutics and, ultimately, multiple disease categories where computational precision can fundamentally reshape patient outcomes. This represents execution at scale, not incremental innovation.” Fiinews.com
